Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure

Table 4

Intervention and follow up.

	Khan	MacDonald	Jones	Hunter	Di Biase	Prabhu	Marrouche
Frequency of monitoring (months)	3 & 6	3 & 6	3,6 & 12	1, 3 & 6	3, 6, 12 & 24	3 & 6	3, 6, 12, 24, 36, 48 & 60
Method of assessing rhythm	Loop recorder	24h holter monitor	48h holter monitor ± existing implantable devices	48h holter monitor	ECG, and existing implantable devices	24h holter monitor and ILR	Existing implantable devices
Repeat procedure	8 (19.5%)	6 (28.6%)	5 (19.2%)	14 (53.8%)	1.4 ± 0.6 per person	Repeat procedure was allowed (frequency not defined)	37 (24.5%)
Crossover	None	None	2	None	None	None	46
Loss to follow-up	None	3	None	1	None	1	33
Ablation strategy	PVI ± Linear lesions ± left atrial complex fractionated electrograms	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cardioversion ± cavotricuspid isthmus ablation	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cardioversion ± cavotricuspid isthmus ablation.	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cavotricuspid isthmus ablation	PVI, and left atrial posterior wall isolation ± SVC isolation ± Linear lesions ± left atrial complex fractionated electrograms ± cardioversion	PVI, left posterior wall isolation ± cardioversion	PVI, Additional ablation lesions were made at the discretion of the operators

PVI: pulmonary veins isolation and SVC: superior vena cava.